Atty Dkt. No: IDD-5657 CIP2

BBL No.: 113957-235

originally filed is also enclosed. Deletions have been made in brackets, and additions have been underlined. No new matter has been added.

## **AMENDMENTS**

## In the Specification:

The following amendments to the Specification have been made in the above-referenced Substitute Specification.

Page 2, line 27, an extra close bracket ")" has been deleted;

Page 2, line 29, "U.S." has been changed to - - United States--;

Page 3, line 4, "U.S." has been changed to -- United States--;

Page 3, line 11, "U.S." has been changed to -- United States - - and "Nos." has been changed to -- No.--.

Page 4, line 21, "presuspension" has been changed to - - pre-suspension--;

Page 4, lines 24-25, "presuspension" has been changed to - - pre-suspension--;

Page 5, lines 1-2, "presuspension" has been changed to - - pre-suspension--;

Page 4, line 3-4, the following paragraph has been inserted:

-- These and other aspects and attributes of the present invention will be discussed with reference to the following drawings and accompanying specification.--

Page 4, line 6, "Not Applicable. The Drawings have been incorporated into the text" has been deleted and replaced with the following:

-- Figure 1 shows a diagrammatic representation of one method of the present invention;

Figure 2 show a diagrammatic representation of another method of the present invention;

Figure 3 shows amorphous particles prior to homogenization;

Figure 4 shows particles after annealing by homogenization;

Figure 5 is an X-Ray diffractogram of microprecipitated itraconazole with polyethylene glycol-660 12-hydroxystearate before and after homogenization;

Figure 6 shows Carbamazepine crystals before homogenization;